布地奈德联合脾氨肽治疗过敏性鼻炎哮喘综合征患儿的临床效果及对VCAM-1和Tim-1的影响

目的探讨布地奈德联合脾氨肽治疗过敏性鼻炎哮喘综合征患儿的临床效果及对血管细胞黏附因子-1(VCAM-1)和T细胞免疫球蛋白域黏蛋白域蛋白-1(Tim-1)的影响。方法选取过敏性鼻炎哮喘综合征200例,根据治疗方法不同将其分为联合治疗组和布地奈德组两组各100例。联合治疗组在雾化吸入布地奈德治疗基础上加用脾氨肽口服液,布地奈德组采用雾化吸入布地奈德治疗,均连续治疗3个月。比较两组治疗前后实验室指标VCAM-1、Tim-1、免疫球蛋白E(IgE)、白细胞介素-4(IL-4)、白细胞介素-5(IL-5)、肿瘤坏死因子-β(TNF-β)、γ-干扰素(IFN-γ)、超氧化物歧化酶(SOD)、丙二醛(MDA)和可溶性细胞间黏附分子-1(sICAM-1)]水平,治疗后临床效果及治疗过程中不良反应发生情况。结果治疗前,两组实验室指标比较差异均无统计学意义(P>0.05)。治疗后,两组VCAM-1、Tim-1、IgE、IL-4、IL-5、MDA和sICAM-1水平低于治疗前,TNF-β、IFN-γ和SOD水平高于治疗前,差异有统计学意义(P<0.05或P<0.01)。治疗后,联合治疗组VCAM-1、Tim-1、IgE、IL-4、IL-5、MDA和sICAM-1水平低于布地奈德组,TNF-β、IFN-γ和SOD水平高于布地奈德组,差异有统计学意义(P<0.05或P<0.01)。治疗后,总有效率联合治疗组为98.00%高于布地奈德组88.00%,差异有统计学意义(P<0.01)。治疗过程中,不良反应总发生率联合治疗组为5.00%高于布地奈德组2.00%,但两组比较差异无统计学意义(P>0.05)。结论布地奈德联合脾氨肽治疗过敏性鼻炎哮喘综合征患儿可调节机体免疫功能,抑制机体炎症反应和氧化应激反应,且效果显著,安全性好。

Clinical Effect of Budesonide Combined with Spleen Aminopeptide in the Treatment of Children with Combined Allergic Rhinitis and Asthma Syndrome and Its Influence on Vascular Cell Adhesion Molecule-1 and T Cell Immunoglobulin Domain and Mucin Domain Protein-1

Objective To investigate the clinical effect of Budesonide combined with Spleen Aminopeptide in the treatment of children with combined allergic rhinitis and asthma syndrome(CARAS)and its influence on the levels of vascular cell adhesion molecule-1(VCAM-1)and T cell immunoglobulin domain and mucin domain protein-1(Tim-1).Methods A total of 200 patients with CARAS were enrolled and randomly divided into combination treatment group(n=100)and Budesonide group(n=100)according to different treatment methods.The combination treatment group was treated with Spleen Aminopeptide oral solution on the basis of Budesonide aerosol inhalation,while the Budesonide group was treated with Budesonide aerosol inhalation for three consecutive months.The levels of laboratory indexesVCAM-1,Tim-1,immunoglobulin E(IgE),interleukin-4(IL-4),interleukin-5(IL-5),tumor necrosis factor-β(TNF-β),interferon-γ(IFN-γ),superoxide dismutase(SOD),malondialdehyde(MDA),and soluble intercellular adhesion molecule-1(sICAM-1)]before and after treatment were compared between the two groups.The clinical effect after treatment and the occurrence of adverse reactions during the treatment were compared.Results Before treatment,there was no significant difference in laboratory indexes between the two groups(P>0.05).After treatment,the levels of VCAM-1,Tim-1,IgE,IL-4,IL-5,MDA and sICAM-1 in the two groups were lower than those before treatment,and the levels of TNF-β,IFN-γand SOD in the two groups were higher than those before treatment(P<0.05 or P<0.01).After treatment,the levels of VCAM-1,Tim-1,IgE,IL-4,IL-5,MDA and sICAM-1 in the combination treatment group were lower than those in the Budesonide group,and the levels of TNF-β,IFN-γand SOD in the combination treatment group were higher than those in the Budesonide group(P<0.05 or P<0.01).After treatment,the total effective rate of combination treatment group was 98.00%,which was significantly higher than that of Budesonide group(88.00%)(P<0.01).During the treatment,the total incidence of adverse reactions in the combination treatment group was 5.00%,which was higher than 2.00%in the Budesonide group,but there was no significant difference between the two groups(P>0.05).Conclusion Budesonide combined with Spleen Aminopeptide in the treatment of children with CARAS can regulate the body's immune function,inhibit the body's inflammatory reaction and oxidative stress reaction,and has significant effect and good safety.